Because other methods are not as sensitive to low allelic fraction events, they may miss important subclonal drivers of progression or resistance. Therefore, the sensitivity of MuTect to detect subclonal mutations with low allele-fractions represents a substantial advance, essential to future discoveries regarding the subclonal architecture of cancer and the translation of those discoveries into clinical diagnostics affecting cancer patient treatment and outcomes.
